로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > Angiopoietin-2

Angiopoietin-2

요약

Name:Angiopoietin-2
Target Synonym:ANGPT2,Angiopoietin 2,ANG-2,Angiopoietin-2B,Angiopoietin-2a,Angiopoietin-2,Tie2-Ligand,AGPT2,ANG2
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:12
Lastest Research Phase:Approved

제품 리스트 구매

일부의 생물활성 데이터

AN2-R52H4-SPR
 Angiopoietin-2 SPR

Rabbit Angiopoietin-2 Protein, His Tag (Cat. No. AN2-R52H4) captured on CM5 chip via anti-His antibody can bind Human TIE2, Fc Tag (Cat. No. TI2-H5255) with an affinity constant of 43.9 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

AN2-H82E9-ELISA
 Angiopoietin-2 ELISA

Immobilized Human TIE2, Fc Tag (Cat. No. TI2-H5255) at 5 μg/mL (100 μL/well) can bind Biotinylated Human Angiopoietin-2 Protein, His,Avitag (Cat. No. AN2-H82E9) with a linear range of 0.005-0.156 μg/mL (QC tested).

사용자 리뷰

Synonym Name

ANGPT2,AGPT2,ANG2,Angiopoietin-2

Background

Angiopoietin-2 is also known as ANGPT2, AGPT2, ANG2, and is a secreted glycoprotein that plays a complex role in angiogenesis and inflammation. Ang2 is widely expressed during development, but it is restricted postnatally to highly angiogenic tissues such as the placenta, ovaries, and uterus. It is particularly abundant in vascular endothelial cells (EC) where it is stored in intracellular Weibel Palade bodies. Both Ang2 and the related Angiopoietin1 (Ang1) are ligands for the receptor tyrosine kinase Tie 2. Ang2 functions as a proangiogenic factor, although it can also induce EC death and vessel regression. Upon its release from quiescent EC, it regulates vascular remodeling by promoting EC survival, proliferation, and migration and destabilizing the interaction between EC and perivascular cells. Ang2 is required for postnatal vascular remodeling, and it cooperates with Ang1 during lymphatic vessel development. It mediates the upregulation of ICAM1 and VCAM1 on EC, which facilitates the adhesion of leukocytes during inflammation. Ang2 competitively inhibit Ang1-induced endothelial cell responses mediated by Tie2, and reduces vascular integrity. But the role of Ang2 is controversial since the opposite outcomes has been reported in other studies. Over-expression of Ang2 disrupts the vascular remodeling, induce endothelial cell apoptosis, and may play an important regulating role in tumor angiogenesis. Ang2 also promotes the neuronal differentiation and migration of subventricular zone progenitor cells.

Clinical and Translational Updates

공개 약품 정보

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Faricimab RO-6867461; RG-7716 Approved F. Hoffmann-La Roche Ltd, Genentech Inc Vabysmo, 罗视佳 United States Diabetic macular oedema; Wet Macular Degeneration Genentech Inc 2022-01-28 Polypoidal choroidal vasculopathy; Macular Edema; Choroid Diseases; Vision Disorders; Retinal Diseases; Diabetic macular oedema; Wet Macular Degeneration; Diabetes Complications; Macular Degeneration; Diabetes Mellitus; Retinal Vein Occlusion; Diabetic Retinopathy; Choroidal Neovascularization Details

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
Zansecimab LY-3127804 Phase 1 Clinical Eli Lilly And Company Solid tumours; Pneumonia; Coronavirus Disease 2019 (COVID-19) Details
RG-6120 RG-6120 Phase 1 Clinical F. Hoffmann-La Roche Ltd Macular Degeneration Details
BI-836880 BI-836880 Phase 2 Clinical Ablynx Nv Neoplasms; Wet Macular Degeneration Details
MEDI-3617 ANG-2-mAb; MEDI-3617; Anti-ANG-2-mAb Phase 1 Clinical Medimmune Ovarian Neoplasms; Solid tumours; Melanoma Details
IBI-324 IBI-324 Phase 1 Clinical Innovent Biologics (Usa), Inc Diabetic macular oedema Details
XMVA09 XMVA-09; XMVA-09 (AAV载体基因治疗药物) Phase 1 Clinical Starry Gene Wet Macular Degeneration Details
Zifibancimig RO-7250284 Phase 1 Clinical F. Hoffmann-La Roche Ltd Macular Degeneration Details
Trebananib AMG-386; 20060439 Phase 2 Clinical Amgen Inc, Takeda Pharmaceutical Co Ltd Lung Neoplasms; Prostatic Neoplasms; Brain Neoplasms; Sarcoma; Carcinoma, Adenosquamous; Peritoneal Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Gliosarcoma; Fallopian Tube Neoplasms; Breast Neoplasms; Uterine Neoplasms; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Endometrial Neoplasms; Neoplasm Metastasis; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Colonic Neoplasms; Solid tumours; Leukemia, Myeloid; Leukemia, Erythroblastic, Acute; Carcinoma; Rectal Neoplasms; Carcinoma, Renal Cell; Hemangiosarcoma; Neoplasms; Ovarian Neoplasms; Kidney Diseases; Glioblastoma; Leukemia, Myelomonocytic, Acute; Central Nervous System Neoplasms; Neuroendocrine Tumors; Leukemia, Megakaryoblastic, Acute; Oligodendroglioma; Sarcoma, Endometrial Stromal Details
Vanucizumab RG-7221; RO-5520985; B800Z06O8K (UNII code) Phase 1 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Neoplasms; Colorectal Neoplasms Details
Y-400 Y-400 Phase 2 Clinical Wuhan Yzy Biopharma Co Ltd Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration Details
EXG102-031 EXG102-031; EXG102-031 (rAAV-based gene therapy) Phase 2 Clinical Hangzhou Jiayin Biotechnology Co Ltd Wet Macular Degeneration; Macular Degeneration Details
ASKG-712 ASKG-712; AM-712 Phase 1 Clinical Askgene Pharma Diabetic macular oedema; Wet Macular Degeneration; Macular Degeneration Details

This web search service is supported by Google Inc.

totop